• Evogene Ltd EVGN.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.30. The mean expectation of two analysts for the quarter was for a loss of 72 cents per share. Wall Street expected results to range from -76 cents to -69 cents per share.

• Revenue rose 178.7% to $1.61 million from a year ago; analysts expected $3.63 million.

• Evogene Ltd's reported EPS for the quarter was 6 cents​.

• The company reported quarterly net income of $427 thousand.

• Evogene Ltd shares had fallen by 24.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Evogene Ltd is $8.13

This summary was machine generated from LSEG data March 6 at 02:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)